secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001558370-24-015429
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio Q3 net loss $19.3M; 4 patients enrolled in FTD-GRN Cohort 2; cash to Q2 2026
--------------------------------------------------------------------------------

- Net loss $19.3M ($0.31/share) vs $27.1M loss a year ago; R&D expenses fell to $8.7M from $15.1M.
- Cash and securities $84.8M at Sept 30, 2024; expected runway to end Q2 2026.
- Enrolled 4 patients in Cohort 2 of upliFT-D trial; 12-month Cohort 1 and interim Cohort 2 data due 1H25.
- Interim Cohort 1 data: PBFT02 raised CSF progranulin for up to 12 months; no serious adverse events with enhanced immunosuppression.
- Appointed Tom Kassberg (Ultragenyx CBO) to board of directors and Audit Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024015429/0001558370-24-015429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024015429/pasg-20241113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer